In a study posted to the bioRxiv* preprint server, a team of researchers from the United States evaluated the protective effect of the preclinical version of the current Moderna Omicron-targeted ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of ...
The highly transmissible omicron (B.1.1.529) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is of mounting concern globally. The omicron variant carries a large number of ...
CAMBRIDGE, MA / ACCESSWIRE / June 8, 2022 / Moderna, Inc., (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced new clinical data on its ...
In early 2021, Qatar launched a mass immunization campaign with the mRNA-1273 (Moderna) 1 vaccine against coronavirus disease 2019 (Covid-19). 2 We assessed the persistence of real-world vaccine ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of ...
In a recent study posted to the Research Square* preprint server and under review at Nature Portfolio journal, researchers tested the safety and immunogenicity of a third dose of coronavirus disease ...
Moderna MRNA announced data from an interim analysis of its phase II/III study — KidCOVE — evaluating its COVID-19 vaccine, mRNA-1273, in two age groups — six months to under two years and two years ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results